CHRS
Coherus BioSciences Inc
1.20$
+0.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 76.1% | 75.5% | 82.2% | 82.7% | 73.1% | 76.2% | 83.6% | 86.5% | 89.2% | 80.0% | 77.5% | 70.0% | |
| 13.8% | 16.3% | 34.0% | 23.6% | 19.3% | 28.1% | 22.2% | 49.4% | 20.0% | 34.4% | 43.3% | 43.4% | |
| 22.5% | 18.7% | 34.0% | 23.6% | 19.3% | 28.1% | 22.2% | 54.1% | 37.1% | 66.6% | 62.8% | 55.1% | |
| 37.1% | 41.4% | 37.2% | 46.5% | 39.4% | 27.3% | 16.8% | 27.2% | 48.5% | 7.1% | 8.5% | 7.5% | |
| 11.4% | 9.9% | 8.1% | 9.2% | 9.4% | 15.6% | 0.9% | 1.0% | 0.4% | 1.2% | 1.8% | 3.0% | |
| 0.2% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | |
| 7.8% | 11.2% | 7.5% | 8.2% | 10.8% | 12.0% | 14.3% | 11.9% | 9.6% | 17.9% | 17.1% | 23.5% | |
| 122.9% | 130.7% | 110.7% | 112.5% | 117.4% | 129.4% | 149.4% | 72.7% | 83.0% | 76.4% | 70.4% | 68.2% | |
| 41.1% | 52.7% | 70.5% | 68.6% | 58.5% | 63.1% | 68.7% | 60.3% | 72.4% | 54.9% | 49.7% | 39.5% | |
| 0.8% | 0.3% | 23.2% | 0.6% | 0.3% | 0.4% | 0.5% | 0.4% | 0.3% | 0.7% | 0.7% | – | |
| 6.4% | 5.6% | 5.0% | 11.4% | 4.3% | 6.3% | 11.0% | 8.6% | 4.8% | 3.8% | 4.3% | 6.9% | |
| 81.0% | 75.2% | 39.2% | 39.1% | 52.4% | 59.1% | 71.5% | 8.4% | 7.2% | 14.3% | 14.0% | 19.5% | |
| -22.9% | -30.7% | -10.7% | -12.5% | -17.4% | -29.4% | -49.4% | 27.3% | 17.0% | 23.6% | 29.6% | 31.8% | |
| -256.9% | -250.9% | -193.4% | -220.7% | -297.1% | -345.8% | -433.2% | -298.0% | -260.5% | -535.3% | -534.3% | -754.2% | |
| 16.7% | 17.7% | 16.4% | 17.0% | 22.8% | 25.7% | 31.2% | 26.4% | 22.5% | 46.6% | 51.3% | 81.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.